Dognosis, a startup co-founded by an Israeli entrepreneur, is currently testing a diagnostic method that integrates the natural olfactory capabilities of dogs with artificial intelligence software. The company claims that its proprietary system can detect seven major types of cancer with a 90% success rate. The process involves training dogs to identify specific scent markers associated with cancerous cells, with AI algorithms then analyzing the data to refine the accuracy of the detection.

While the company’s internal data suggests high performance, the scientific community has expressed a measured response. Experts in the field of oncology and diagnostic technology note that while canine scent detection has shown promise in various clinical studies, scaling such a system for widespread medical use presents significant logistical and scientific challenges. Critics point out that clinical validation is a rigorous, multi-stage process, and the company has yet to provide peer-reviewed evidence that would satisfy the broader medical community. Consequently, while the preliminary results are being presented as a breakthrough, industry observers emphasize that further independent testing is required to confirm whether this technology can reliably function in a clinical setting or if it is merely a proof-of-concept at this stage.